Terumo Corporation to expand existing cleanroom manufacturing facilities at its subsidiary Vascutek located near Glasgow
Investmet to significantly scale up existing facilities at the site, including two new cleanrooms
Terumo Corporation, a Tokyo-based medical device manufacturer, has announced a £33 million capital investment in one of its subsidiaries, Vascutek Limited, located near Glasgow.
The investment has been approved for the expansion of Vascutek's headquarters and manufacturing facility at Inchinnan, Renfrewshire – in the west central Lowlands – to help drive further growth for the global medical device company.
Vascutek produces a comprehensive portfolio of implants with a particular focus on treating patients with aortic disease. These implants have been delivered to two million patients in over 100 countries worldwide. Over 90% of the products made at Inchinnan are exported.
The investment will be used to significantly scale up existing facilities at the site, including two new cleanrooms. These will be used in the manufacture of polyester grafts and Thoraflex Hybrid products.
Other aspects of the investment include equipment for the cleanrooms and a new sterilization suite. The first phase of the site development is due to start in April 2018 and is scheduled for completion in 2021.
Paul Holbrook, president and CEO of Vascutek, said: “This is an extremely exciting time for the company as we look to secure further growth in the surgical grafts market. The investment from Terumo is a testament to the quality, efficiency and excellent customer service delivered consistently by our team at Inchinnan and will allow us to further expand our business globally."
Vascutek produces a portfolio of implants for treating patients with aortic disease
The decision to invest in the Scottish manufacturing site, Holbrook said, sends a strong signal about the health of the company and its prospects for the future. "It is an important milestone in our mission to create innovative products to the highest standard that benefit the lives of patients and their families across the world," he concluded.
Established in 1982, Vascutek employs around 800 staff at its Inchinnan base. It applies advanced and innovative technologies to develop its products, which include an extensive range of sealed woven and knitted polyester grafts for peripheral, abdominal and cardiothoracic surgery, ePTFE grafts and a custom AAA stent graft system.
In the UK, the company has been granted eight 'Queen's Awards for Enterprise', with the most recent in 2016 for Innovation following the development of a unique surgical graft, Thoraflex Hybrid used in treating thoracic aortic disease and which has been implanted in over 3,000 patients since its launch in 2012.
Terumo Corporation of Japan, a global medical device company which was founded in 1921 and currently has over 22,000 employees worldwide. It acquired Vascutek in 2002.
The Vascular Graft Division of Terumo is powered by Vascutek and Bolton Medical, Inc., which joined Terumo in March 2017.